While some preclinical studies reported that ETA-selective or dual ET receptor blockers (ERAs) improve ischemic stroke outcomes and cognitive impairment, there are also conflicting reports with selective ETB agonism preventing the development of cognitive impairment (Li et al., 2018). The gene discussed is EDNRB; the disease is Cognitive impairment.